Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
Aguilar-Perez, Clara Gracia, Begona Rodrigues, Liliana Vitoria, Asuncion Cebrian, Ruben Deboosere, Nathalie Song, Ok-Ryul Brodin, Priscille Maqueda, Mercedes Ainsa, Jose A.
Antimicrobial agents and chemotherapy, 2018
https://doi.org/10.1128/aac.00359-18
Mercedes Maqueda
Maqueda Mercedes
ORCID: 0000-0002-5874-9343
A transferable plasmid associated with AS-48 production in enterococcus faecalis 10.1128/jb.172.5.2817-2818.1990
Effect of combined physico-chemical preservatives on enterocin AS-48 activity against the enterotoxigenic Staphylococcus aureus CECT 976 strain 10.1111/j.1365-2672.2004.02276.x
Control of Staphylococcus aureus in sausages by enterocin AS-48 10.1016/j.meatsci.2005.04.039
Prevention of spoilage by enterocin AS-48 combined with chemical preservatives, under vacuum, or modified atmosphere in a cooked ham model 10.1016/j.foodcont.2011.08.001
Purification of amoebolytic substances from Bacillus licheniformis M-4 10.1007/BF00264380
Fast, convenient, and economical method for isolating genomic DNA from lactic acid bacteria using a modification of the protein "salting-out" procedure 10.1016/j.ab.2007.03.010
Polyphasic study of microbial communities of two Spanish farmhouse goats' milk cheeses from Sierra de Aracena 10.1016/j.fm.2008.12.004
Expression of linear permutated variants from circular enterocin AS-48 10.1016/j.biochi.2010.11.011
Heterologous expression of enterocin AS-48 in several strains of lactic acid bacteria 10.1111/j.1365-2672.2006.03194.x
Synergy between circular bacteriocin AS-48 and ethambutol against mycobacterium tuberculosis 10.1128/AAC.00359-18
Application of the broad-spectrum bacteriocin enterocin AS-48 to inhibit Bacillus coagulans in canned fruit and vegetable foods 10.1016/j.fct.2006.05.019
Induction of autolysis in Enterococcus faecalis S‐47 by peptide AS‐48 10.1111/j.1365-2672.1990.tb01531.x
Characterization and biological activity against Naegleria fowleri of amoebicins produced by Bacillus licheniformis D-13 10.1128/AAC.38.6.1314
Inhibition of Staphylococcus aureus in dairy products by enterocin AS-48 produced in situ and ex situ: Bactericidal synergism with heat 10.1016/j.idairyj.2006.09.006
Structure of bacteriocin AS-48: From soluble state to membrane bound state 10.1016/j.jmb.2003.09.060
Characterization of a new operon, as-48EFGH, from the as-48 gene cluster involved in immunity to enterocin AS-48 10.1128/AEM.69.2.1229-1236.2003
The denaturation of circular enterocin AS-48 by urea and guanidinium hydrochloride 10.1016/S0167-4838(02)00341-2
Widespread production of AS-48-like bactericins in strains of Enterococcus faecalis? [2] 10.1046/j.1365-2958.1998.01020.x
Processing of as-48ABC RNA in AS-48 enterocin production by Enterococcus faecalis 10.1128/JB.01528-07
Control of Alicyclobacillus acidoterrestris in fruit juices by enterocin AS-48 10.1016/j.ijfoodmicro.2005.03.010
Antimicrobial characterization and safety aspects of the bacteriocinogenic Enterococcus hirae F420 isolated from Moroccan raw goat milk 10.1139/W2012-027
Analysis of the promoters involved in enterocin AS-48 expression 10.1371/journal.pone.0090603
Characterization and safety evaluation of enterococci isolated from Spanish goats' milk cheeses 10.1016/j.ijfoodmicro.2009.03.010
Evolution of the phenolic compounds profile of olive leaf extract encapsulated by spray-drying during in vitro gastrointestinal digestion 10.1016/j.foodchem.2018.11.127
Control of Listeria monocytogenes in goat's milk and goat's jben by the bacteriocinogenic Enterococcus faecium F58 strain 10.4315/0362-028X-69.10.2370
Enterocin AS-48RJ: A variant of enterocin AS-48 chromosomally encoded by Enterococcus faecium RJ16 isolated from food 10.1016/j.syapm.2005.01.007
Bacteriocin plasmid pBM1 of Enterococcus faecalis: Identification of the cell aggregation substance after induction by sex pheromone 10.1139/m94-081
Genetic features of circular bacteriocins produced by Gram-positive bacteria 10.1111/j.1574-6976.2007.00087.x
Discovering the bacterial circular proteins: Bacteriocins, cyanobactins, and pilins 10.1074/jbc.R112.354688
Polyphasic approach to bacterial dynamics during the ripening of Spanish farmhouse cheese, using culture-dependent and -independent methods 10.1128/AEM.00418-08
Insights into the functionality of the putative residues involved in enterocin AS-48 maturation 10.1128/AEM.01154-10
The bacteriocin AS-48 requires dimer dissociation followed by hydrophobic interactions with the membrane for antibacterial activity 10.1016/j.jsb.2015.03.006
Isolation and characterization of enterocin EJ97, a bacteriocin produced by Enterococcus faecalis EJ97 10.1007/s002030050678
Enterocin AS-48 as evidence for the use of bacteriocins as new leishmanicidal agents 10.1128/AAC.02288-16
Use of alkenylresorcinols from Ononis Speciosa as synthetic precursors of compounds with potential biological activity 10.1021/np50100a012
Biocontrol of psychrotrophic enterotoxigenic Bacillus cereus in a nonfat hard cheese by an enterococcal strain-producing enterocin AS-48 10.4315/0362-028X-67.7.1517
Inhibition of bacterial growth, enterotoxin production, and spore outgrowth in strains of Bacillus cereus by bacteriocin AS-48 10.1128/AEM.68.3.1473-1477.2002
Control of Listeria monocytogenes in model sausages by enterocin AS-48 10.1016/j.ijfoodmicro.2004.12.024
Physical mapping of the conjugative plasmid pMB1-1 of Enterococcus faecalis 10.1046/j.1472-765X.1998.00417.x
Effect of replacing glutamic residues upon the biological activity and stability of the circular enterocin AS-48 10.1093/jac/dkn126
Influence of physico-chemical factors on the oligomerization and biological activity of bacteriocin AS-48 10.1007/s0028403335
Assessing in vitro digestibility of food biopreservative AS-48 10.1016/j.foodchem.2017.10.149
Characterization and partial purification of a broad spectrum antibiotic AS-48 produced by Streptococcus faecalis 10.1139/m86-141
Treatment of vegetable sauces with enterocin AS-48 alone or in combination with phenolic compounds to inhibit proliferation of Staphylococcus aureus 10.4315/0362-028X-70.2.405
Design, NMR characterization and activity of a 21-residue peptide fragment of bacteriocin AS-48 containing its putative membrane interacting region 10.1002/psc.589
AS-48: A circular protein with an extremely stable globular structure 10.1016/S0014-5793(01)02841-1
Effect of combined physico-chemical treatments based on enterocin AS-48 on the control of Listeria monocytogenes and Staphylococcus aureus in a model cooked ham 10.1016/j.foodcont.2009.07.010
Characterization of functional, safety, and gut survival related characteristics of Lactobacillus strains isolated from farmhouse goat's milk cheeses 10.1016/j.ijfoodmicro.2013.02.015
Isolation and physico-chemical characterization of an antifungal and antibacterial peptide produced by Bacillus licheniformis A12 10.1007/BF00205029
Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48 10.1016/j.ijpddr.2018.03.002
Sequence-specific1H assignment and secondary structure of the bacteriocin AS-48 cyclic peptide 10.1023/A:1008267725043
Purification, characterization, and biological effects of a second bacteriocin from Enterococcus faecalis ssp. liquefaciens S-48 and its mutant strain B-48-28 10.1139/m91-132
Insights into Chagas treatment based on the potential of bacteriocin AS-48 10.1016/j.ijpddr.2019.03.003
Peptide AS-48: Prototype of a new class of cyclic bacteriocins 10.2174/1389203043379567
Are bacteriocins underexploited? NOVEL applications for OLD antimicrobials 10.2174/138920111796117364
Incidence of antibiotic resistance and sex pheromone response among enterococci isolated from clinical human samples and from municipal waste water 10.1111/j.1365-2672.1996.tb03544.x
Analysis of the gene cluster involved in production and immunity of the peptide antibiotic AS-48 in Enterococcus faecalis 10.1046/j.1365-2958.1998.00682.x
Permeation of bacterial cells, permeation of cytoplasmic and artificial membrane vesicles, and channel formation on lipid bilayers by peptide antibiotic AS-48 10.1128/jb.173.2.886-892.1991
AS-48 bacteriocin: Close to perfection 10.1007/s00018-011-0724-4
Monolayer characteristics of bacteriocin AS-48, pH effect and interactions with dipalmitoyl phosphatidic acid at the air - Water interface 10.1006/jcis.2000.7239
Bactericidal action of peptide antibiotic AS-48 against Escherichia coli K-12 10.1139/m89-048
Bacteriocin AS-48, a microbial cyclic polypeptide structurally and functionally related to mammalian NK-lysin 10.1073/pnas.210301097
Characterization of linear forms of the circular enterocin AS-48 obtained by limited proteolysis 10.1016/j.febslet.2008.08.018
Application of enterocin AS-48 as biopreservative in eggs and egg fractions: Synergism through lysozyme 10.1016/j.lwt.2017.11.018
Biodiversity of the microbial community in a Spanish farmhouse cheese as revealed by culture-dependent and culture-independent methods 10.1016/j.ijfoodmicro.2008.07.004
Antagonistic Action of the Bacterium Bacillus Licheniformis M‐4 Toward the Amoeba Naegleria Fowleri 10.1111/j.1550-7408.1993.tb04923.x
The impact of enterocin AS-48 on the shelf-life and safety of sardines (Sardina pilchardus) under different storage conditions 10.1016/j.fm.2014.06.008
Structural characterisation of the natively unfolded enterocin EJ97 10.1093/protein/gzq020
Optimization of enterocin AS-48 production on a whey-based substrate 10.1016/j.idairyj.2008.02.001
Bactericidal and bacteriolytic action of peptide antibiotic AS-48 against gram-positive and gram-negative bacteria and other organisms 10.1016/0923-2508(89)90060-0
Growth of an Acanthamoeba isolate on a gram-negative bacterium, probably Pasteurella haemolytica 10.2307/3282069
Biocontrol of Listeria monocytogenes in fish by enterocin AS-48 and Listeria lytic bacteriophage P100 10.1016/j.lwt.2015.11.025
pS86, a new theta-replicating plasmid from Enterococcus faecalis 10.1007/s002840010130
Stability of enterocin AS-48 in fruit and vegetable juices 10.4315/0362-028X-68.10.2085
Effect of peptide AS-48 on Enterococcus faecalis subsp. liquifaciens S-47 10.1128/AAC.33.5.641
A simple method for semi-preparative-scale production and recovery of enterocin AS-48 derived from Enterococcus faecalis subsp. liquefaciens A-48-32 10.1016/S0167-7012(03)00202-1
Optimization of genotypic and biochemical methods to profile P. acnes isolates from a patient population 10.1016/j.mimet.2017.07.008
Characterization of functional, safety, and probiotic properties of Enterococcus faecalis UGRA10, a new AS-48-producer strain 10.1016/j.fm.2011.12.002
Effect of immersion solutions containing enterocin AS-48 on Listeria monocytogenes in vegetable foods 10.1128/AEM.71.12.7781-7787.2005
Biological activity of amoebicin m4-A from Bacillus licheniformis M-4 10.1128/AAC.38.8.1820
Conformational stability and activity of circular enterocin as-48 derivatives 10.2174/092986610791190390
Induction of inhibitory agent produced by Enterococcus faecalis 10.1007/BF02820768
Genetic stability of the antagonistic character of Enterococcus faecalis ssp. liquefaciens and the detection of a new inhibitory bacteriocin-like substance 10.1007/BF02820767
Bactericidal synergism through enterocin AS-48 and chemical preservatives against Staphylococcus aureus 10.1111/j.1472-765X.2007.02155.x
Transfer of a plasmid determining bacteriocin Bc-48 production and immunity, and response to sexual pheromones in Enterococcus faecalis S-48 10.1016/0147-619X(92)90036-A
Neutralizing antibodies against the peptide antibiotic AS-48: Immunocytological studies 10.1128/AAC.37.1.148
Evaluation of an enterocin AS-48 enriched bioactive powder obtained by spray drying 10.1016/j.fm.2009.08.002
Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme 10.1038/s41598-018-29580-7
Determination of the gene sequence and the molecular structure of the enterococcal peptide antibiotic AS-48 10.1128/jb.176.20.6334-6339.1994
Purification of sex pheromones specific for pMB1 and pMB2 plasmids of Enterococcus faecalis S-48 10.1139/m95-084
Inhibition of toxicogenic Bacillus cereus in rice-based foods by enterocin AS-48 10.1016/j.ijfoodmicro.2005.08.003
Purification and amino acid composition of peptide antibiotic AS-48 produced by Streptococcus (Enterococcus) faecalis subsp. liquefaciens S-48 10.1128/AAC.33.4.437
Synergistic effect of enterocin AS-48 in combination with outer membrane permeabilizing treatments against Escherichia coli O157:H7 10.1111/j.1365-2672.2005.02733.x
Fungicin M4: a narrow spectrum peptide antibiotic from Bacillus licheniformis M‐4 10.1111/j.1365-2672.1994.tb03043.x
Combined effect of enterocin AS-48 and high hydrostatic pressure to control food-borne pathogens inoculated in low acid fermented sausages 10.1016/j.meatsci.2009.10.017
Inhibition of Bacillus licheniformis LMG 19409 from ropy cider by enterocin AS-48 10.1111/j.1365-2672.2006.02942.x
Characterization of antimicrobial substances produced by Enterococcus faecalis MRR 10-3, isolated from the uropygial gland of the hoopoe (Upupa epops) 10.1128/AEM.02940-05
Enterococcus faecium F58, a bacteriocinogenic strain naturally occurring in Jben, a soft, farmhouse goat's cheese made in Morocco 10.1111/j.1365-2672.2005.02586.x
The genes coding for enterocin EJ97 production by Enterococcus faecalis EJ97 are located on a conjugative plasmid 10.1128/AEM.69.3.1633-1641.2003
LAB bacteriocins controlling the food isolated (drug-resistant) staphylococci 10.3389/fmicb.2018.01143
The cyclic structure of the enterococcal peptide antibiotic AS-48 10.1016/0014-5793(94)00925-2
Subchronic toxicity study in BALBc mice of enterocin AS-48, an anti-microbial peptide produced by Enterococcus faecalis UGRA10 10.1016/j.fct.2019.110667
Role of maltodextrin and inulin as encapsulating agents on the protection of oleuropein during in vitro gastrointestinal digestion 10.1016/j.foodchem.2019.125976
Preclinical studies of toxicity and safety of the AS-48 bacteriocin 10.1016/j.jare.2019.06.003
Egg Production in Poultry Farming Is Improved by Probiotic Bacteria. 10.3389/fmicb.2019.01042
The potential of bacteriocin AS-48 in the control of Propionibacterium acnes 10.7287/peerj.preprints.2107v1
Physical mapping of the conjugative plasmid pMB1-1 of Enterococcus faecalis. 10.1046/j.1472-765x.1998.t01-1-00417.x
Purification of amoebolytic substances from Bacillus licheniformis M-4. 10.1007/s002030050108
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
José Antonio Aínsa Claver
Aínsa Claver José Antonio / José Antonio Aínsa
ORCID: 0000-0003-2076-844X
Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies 10.3390/ijms221810137
Design, synthesis and inhibitory activity against Mycobacterium tuberculosis thymidine monophosphate kinase of acyclic nucleoside analogues with a distal imidazoquinolinone 10.1016/j.ejmech.2010.09.056
Transcriptional analysis of and resistance level conferred by the aminoglycoside acetyltransferase gene aac(2')-Id from Mycobacterium smegmatis. 10.1093/jac/dkm440
Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: Characterization of the aac(2')-lc gene from Mycobacterium tuberculosis and the aac(2')-ld gene from Mycobacterium smegmatis 10.1046/j.1365-2958.1997.3471717.x
Construction of a family of Mycobacterium/Escherichia coli shuttle vectors derived from pAL5000 and pACYC184: Their use for cloning an antibiotic-resistance gene from Mycobacterium fortuitum 10.1016/0378-1119(96)00202-8
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux 10.1038/nm.3458
Analysis of Mutations in Streptomycin-Resistant Strains Reveals a Simple and Reliable Genetic Marker for Identification of the Mycobacterium tuberculosis Beijing Genotype 10.1128/JCM.01944-12
Zanthoxylum capense constituents with antimycobacterial activity against Mycobacterium tuberculosis in vitro and ex vivo within human macrophages 10.1016/j.jep.2013.01.013
Role of the Mmr Efflux Pump in Drug Resistance in Mycobacterium tuberculosis 10.1128/AAC.01482-12
Mycobacterial Shuttle Vectors Designed for High-Level Protein Expression in Infected Macrophages 10.1128/AEM.01674-12
Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG 10.1128/AAC.05946-11
A Prodrug Approach for Improving Antituberculosis Activity of Potent Mycobacterium tuberculosis Type II Dehydroquinase Inhibitors 10.1021/jm2006063
Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique 10.1016/j.jep.2011.04.062
The complex whiJ locus mediates environmentally sensitive repression of development of Streptomyces coelicolor A3(2) 10.1007/s10482-010-9443-3
Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth 10.1128/AAC.00550-09
Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG 10.1093/jac/dkl510
Novel streptomycin resistance gene from Mycobacterium fortuitum 10.1128/AAC.00223-06
Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum 10.1093/jac/dki436
Role of mycobacterial efflux transporters in drug resistance: an unresolved question. 10.1111/j.1574-6976.2005.00002.x
Molecular approaches to tuberculosis. 10.1046/j.1365-2958.2001.02652.x
Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis 10.1128/AAC.45.3.800-804.2001
WhiA, a protein of unknown function conserved among gram-positive bacteria, is essential for sporulation in Streptomyces coelicolor A3(2) 10.1128/JB.182.19.5470-5478.2000
A response regulator-like protein that functions at an intermediate stage of sporulation in Streptomyces coelicolor A3(2) 10.1046/j.1365-2958.1999.01630.x
Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. 10.1586/eri.12.89
Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development 10.1016/j.bcp.2015.05.001
Measuring efflux and permeability in mycobacteria. 10.1007/978-1-4939-2450-9_13
Antituberculosis drugs: reducing efflux = increasing activity 10.1016/j.drudis.2017.01.002
Discovery of antimicrobial compounds targeting bacterial type FAD synthetases 10.1080/14756366.2017.1411910
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. 10.1016/j.tube.2018.08.004
Total Synthesis of Ripostatin B and Structure-Activity Relationship Studies on Ripostatin Analogs. 10.1021/acs.joc.8b00193
Ionophore A23187 shows anti-tuberculosis activity and synergy with tebipenem. 10.1016/j.tube.2017.09.001
Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors. 10.1021/acs.jmedchem.7b01570
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. 10.1021/acsinfecdis.6b00158
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Boldine-Derived Alkaloids Inhibit the Activity of DNA Topoisomerase I and Growth of Mycobacterium tuberculosis. 10.3389/fmicb.2018.01659
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis. 10.1128/aac.00359-18
Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. 10.2174/157489111796064579
Isolation by genetic labeling of a new mycobacterial plasmid, pJAZ38, from Mycobacterium fortuitum. 10.1128/jb.179.13.4115-4122.1997
New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules https://doi.org/10.1016/j.cej.2017.12.110
Polypeptidic Micelles Stabilized with Sodium Alginate Enhance the Activity of Encapsulated Bedaquiline 10.1002/mabi.201800397
Co-delivery of free vancomycin and transcription factor decoy-nanostructured lipid carriers can enhance inhibition of methicillin resistant Staphylococcus aureus (MRSA) 10.1371/journal.pone.0220684
In silico discovery and biological validation of ligands of FAD synthase, a promising new antimicrobial target 10.1371/journal.pcbi.1007898
Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis 10.1002/adtp.202000113
Liliana Rodrigues
Rodrigues Liliana
ORCID: 0000-0002-2094-2666
Measuring efflux and permeability in mycobacteria. 10.1007/978-1-4939-2450-9_13
Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. 10.1128/aac.01482-12
Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. 10.1586/eri.12.89
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. 10.1371/journal.pone.0034538
Genetic response of Salmonella enterica serotype Enteritidis to thioridazine rendering the organism resistant to the agent. 10.1016/j.ijantimicag.2011.08.013
Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. 10.1016/j.meegid.2011.08.009
Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. 10.2174/157489111796064579
Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. 10.1186/1471-2180-11-35
Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant Enterobacter aerogenes. 10.1016/j.ijantimicag.2010.06.036
Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. 10.1586/eri.10.20
Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. 10.1007/978-1-60327-279-7_12
Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. 10.1186/1754-1611-3-18
Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study. 10.1111/j.1469-0691.2009.03076.x
The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. 10.1016/j.ijantimicag.2009.07.010
An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. 10.1016/j.ijantimicag.2009.06.029
pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. 10.1371/journal.pone.0006656
New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. 10.2174/138945008785747734
Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. 10.1016/j.ijantimicag.2007.12.015
Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. 10.1093/jac/dkn070
Antibiotic stress, genetic response and altered permeability of E. coli. 10.1371/journal.pone.0000365
Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. 10.1128/jcm.43.9.4880-4884.2005
Antituberculosis drugs: reducing efflux=increasing activity. 10.1016/j.drudis.2017.01.002
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis. 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. 10.1016/j.tube.2018.08.004
Boldine-Derived Alkaloids Inhibit the Activity of DNA Topoisomerase I and Growth of Mycobacterium tuberculosis. 10.3389/fmicb.2018.01659
Total Synthesis of Ripostatin B and Structure-Activity Relationship Studies on Ripostatin Analogs. 10.1021/acs.joc.8b00193
Mycobacterial Aminoglycoside Acetyltransferases: A Little of Drug Resistance, and a Lot of Other Roles. 10.3389/fmicb.2019.00046
Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice 10.1021/acs.jmedchem.9b00355
O contributo dos serviços de diagnóstico laboratorial para o acesso universal à saúde nos países da Comunidade de Língua Portuguesa 10.25761/ANAISIHMT.337
RUBEN CEBRIAN
CEBRIAN RUBEN / Rubén Cebrián Castillo
ORCID: 0000-0003-1575-1846
Insights into the Functionality of the Putative Residues Involved in Enterocin AS-48 Maturation 10.1128/aem.01154-10
AS-48 bacteriocin: close to perfection 10.1007/s00018-011-0724-4
Characterization of functional, safety, and probiotic properties of Enterococcus faecalis UGRA10, a new AS-48-producer strain 10.1016/j.fm.2011.12.002
Antimicrobial characterization and safety aspects of the bacteriocinogenic Enterococcus hirae F420 isolated from Moroccan raw goat milk 10.1139/w2012-027
Discovering the Bacterial Circular Proteins: Bacteriocins, Cyanobactins, and Pilins 10.1074/jbc.r112.354688
Analysis of the Promoters Involved in Enterocin AS-48 Expression 10.1371/journal.pone.0090603
The bacteriocin AS-48 requires dimer dissociation followed by hydrophobic interactions with the membrane for antibacterial activity 10.1016/j.jsb.2015.03.006
Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents 10.1128/aac.02288-16
Optimization of genotypic and biochemical methods to profile P. acnes isolates from a patient population 10.1016/j.mimet.2017.07.008
Assessing in vitro digestibility of food biopreservative AS-48 10.1016/j.foodchem.2017.10.149
Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48 10.1016/j.ijpddr.2018.03.002
LAB Bacteriocins Controlling the Food Isolated (Drug-Resistant) Staphylococci 10.3389/fmicb.2018.01143
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme 10.1038/s41598-018-29580-7
Evolution of the phenolic compounds profile of olive leaf extract encapsulated by spray-drying during in vitro gastrointestinal digestion 10.1016/j.foodchem.2018.11.127
Insights into Chagas treatment based on the potential of bacteriocin AS-48 10.1016/j.ijpddr.2019.03.003
Preclinical studies of toxicity and safety of the AS-48 bacteriocin 10.1016/j.jare.2019.06.003
Design and Expression of Specific Hybrid Lantibiotics Active Against Pathogenic Clostridium spp. 10.3389/fmicb.2019.02154
Role of maltodextrin and inulin as encapsulating agents on the protection of oleuropein during in vitro gastrointestinal digestion 10.1016/j.foodchem.2019.125976
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci 10.3390/antibiotics9090567
Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease. 10.1093/jac/dkaa030
High-Throughput Screening for Substrate Specificity-Adapted Mutants of the Nisin Dehydratase NisB. 10.1021/acssynbio.0c00130
Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens. 10.1038/s42003-020-01511-1
Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant Staphylococcus aureus 10.3390/antibiotics10080925
Elucidating the mechanism by which synthetic helper peptides sensitize Pseudomonas aeruginosa to multiple antibiotics 10.1371/journal.ppat.1009909
Summary of the Sussex-Huawei locomotion-transportation recognition challenge
Observation of a manifold in the chaotic phase space of an asymmetric optical microcavity
Localized temporal variation of Earth's inner-core boundary from high-quality waveform doublets
Off-axis multi-wavelength dispersion controlling metalens for multi-color imaging
Impact of United States political sanctions on international collaborations and research in Iran